After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer
pharmaphorum
DECEMBER 23, 2022
price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. The animal results showed dose-dependent tumour growth inhibition and efficacy beyond the treatment window, despite clearance of drug from blood and tissues.
Let's personalize your content